Eli Lilly and Company (NYSE:LLY) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI

Schaper Benz & Wise Investment Counsel Inc. WI lifted its stake in Eli Lilly and Company (NYSE:LLY) by 35.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 550 shares of the company’s stock after purchasing an additional 143 shares during the quarter. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Eli Lilly and Company were worth $487,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lynx Investment Advisory purchased a new position in Eli Lilly and Company during the second quarter worth about $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Morton Brown Family Wealth LLC lifted its holdings in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares during the last quarter. Finally, Cedar Mountain Advisors LLC lifted its holdings in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after acquiring an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $917.97 on Monday. The business has a 50-day simple moving average of $921.21 and a 200-day simple moving average of $858.60. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The company has a market cap of $872.44 billion, a PE ratio of 135.19, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on LLY shares. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday. They issued an “outperform” rating and a $1,100.00 target price on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.